Early Detection Research Network

Tsay176, Jun-chieh

Contact Information

Email: mailto:tsayj01@nyumc.org
Fax:
3861
Co-Principal Investigator
None given

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

None Available.

Closed Protocols

No closed protocols.

Publications

Publication Name PubMed ID Journal
A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. 24132637 Sci Transl Med
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. 29622464 Cancer Cell
A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT. 30487137 Cancer Res.
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. 17251920 Nat. Rev. Cancer
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. 27596916 Ann. Thorac. Surg.
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. 29625054 Cell
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. 30268436 Cell Syst
A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA. 28855354 Clin. Cancer Res.
A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations. 30376426 J. Clin. Oncol.
Aberrant methylation of p21 gene in lung cancer and malignant pleural mesothelioma. 21709715 Acta Med. Okayama
Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. 17096329 Int. J. Cancer
Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. 29864375 Am. J. Respir. Crit. Care Med.
An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. 21454801 Am. J. Respir. Cell Mol. Biol.
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. 29625055 Cell
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. 16221779 N. Engl. J. Med.
Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. 29496499 Chest
Autoantibodies against tumor-associated antigens in the early detection of lung cancer. 27565936 Lung Cancer
Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation. 24722292 Cell Death Dis
BAP1 regulates IP3R3-mediated Ca<sup>2+</sup> flux to mitochondria suppressing cell transformation. 28614305 Nature
Biomarkers and molecular testing for early detection, diagnosis, and therapeutic prediction of lung cancer. 23566973 Thorac Surg Clin
Biomarkers and prognostic factors for mesothelioma. 23977535 Ann Cardiothorac Surg
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know. 24623168 Eur J Cardiothorac Surg
Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. 21159167 Mol. Cancer
Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium. 26279647 Clin Proteomics
Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. 22552293 Cancer Res.
CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells. 24598827 PLoS ONE
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. 29625048 Cell
Cellular and molecular parameters of mesothelioma. 16795078 J. Cell. Biochem.
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. 29622466 Cancer Cell
Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules. 26896032 J Thorac Oncol
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. 30078747 Cancer Cell
Comprehensive Characterization of Cancer Driver Genes and Mutations. 29625053 Cell
Comprehensive Characterization of Cancer Driver Genes and Mutations. 30096302 Cell
Comprehensive Characterization of Cancer Driver Genes and Mutations. 29625053 Cell
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. 30380420 Cell Rep
Comprehensive molecular profiling of lung adenocarcinoma. 25079552 Nature
CREB-induced inflammation is important for malignant mesothelioma growth. 25111229 Am. J. Pathol.
Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. 16966607 Proc. Natl. Acad. Sci. U.S.A.
Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma. 21620418 J. Thorac. Cardiovasc. Surg.
Diagnosis and prognosis-review of biomarkers for mesothelioma. 28706912 Ann Transl Med
Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. 19273703 J. Clin. Oncol.
Differential N-Glycosylation Patterns in Lung Adenocarcinoma Tissue. 26322380 J. Proteome Res.
Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. 15639718 Lung Cancer
DNA copy number gains in malignant pleural mesothelioma. 26722325 Oncol Lett
DNA methylation profile of 28 potential marker loci in malignant mesothelioma. 17659810 Lung Cancer
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. 29617662 Cell Rep
Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. 23056237 PLoS ONE
Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. 21673066 Clin. Cancer Res.
Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma. 29980786 Oncogene
ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. 21710492 Int. J. Cancer
Evaluation of clonal origin of malignant mesothelioma. 25471750 J Transl Med
Exosomal miR-16-5p as a target for malignant mesothelioma. 31406207 Sci Rep
Expression of Concern: HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. 32169964 Clin. Cancer Res.
Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. 24669013 Ann. Oncol.
Extracellular mRNA Detected by Tethered Lipoplex Nanoparticle Biochip for Lung Adenocarcinoma Detection. 27304243 Am. J. Respir. Crit. Care Med.
Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma. 29416614 Oncotarget
Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas. 23446998 Clin. Cancer Res.
Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. 30410729 F1000Res
Fibulin-3 as a biomarker for pleural mesothelioma. 23301743 N. Engl. J. Med.
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. 23050525 N. Engl. J. Med.
Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. 20689445 J Thorac Oncol
Genomic and Functional Approaches to Understanding Cancer Aneuploidy. 29622463 Cancer Cell
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. 29617664 Cell Rep
Genomic events associated with progression of pleural malignant mesothelioma. 18973227 Int. J. Cancer
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. 29617660 Cell Rep
Germline BAP1 mutations predispose to malignant mesothelioma. 21874000 Nat. Genet.
Germline BAP1 mutations induce a Warburg effect. 28665402 Cell Death Differ.
Heparanase inhibitors restrain mesothelioma. 30627323 Oncotarget
HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. 17872495 Am. J. Respir. Cell Mol. Biol.
High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. 25658628 J Thorac Oncol
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. 27834213 Proc. Natl. Acad. Sci. U.S.A.
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. 26733616 Clin. Cancer Res.
HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. 28186988 Oncotarget
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. 20160038 Cancer Res.
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. 29311642 Oncogene
Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer. 28638733 Oncoimmunology
Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). 15777968 Lung Cancer
Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung. 15246191 Lung Cancer
Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin. 27486763 Oncotarget
Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma. 28759042 Oncogene
Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. 29617661 Cell Rep
Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma. 28049629 Carcinogenesis
Integrative Molecular Characterization of Malignant Pleural Mesothelioma. 30322867 Cancer Discov
Integrative Molecular Characterization of Malignant Pleural Mesothelioma. 30322867 Cancer Discov
Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications. 29579286 J. Natl. Cancer Inst.
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. 28967920 Nat. Med.
lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. 29622465 Cancer Cell
Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. 19818970 J. Thorac. Cardiovasc. Surg.
Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. 29617658 Cell Rep
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. 29625051 Cell
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. 22980975 Cell
Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. 19852844 Mol. Cancer
MESOMARK: a potential test for malignant pleural mesothelioma. 17289801 Clin. Chem.
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. 25380601 Carcinogenesis
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. 18093943 Proc. Natl. Acad. Sci. U.S.A.
Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. 25657018 Cancer Prev Res (Phila)
Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options. 25421663 Methods Mol. Biol.
microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. 23945385 J Thorac Oncol
Molecular characterization of the peripheral airway field of cancerization in lung adenocarcinoma. 25705890 PLoS ONE
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. 29617665 Cell Rep
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. 31278276 Nat Commun
Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1. 31257023 Cell
Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. 16243798 Clin. Cancer Res.
Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. 19309490 Histopathology
Oncogenic Signaling Pathways in The Cancer Genome Atlas. 29625050 Cell
Onconase mediated NFKβ downregulation in malignant pleural mesothelioma. 21317924 Oncogene
Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. 19047145 Cancer Res.
Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. 20924114 Cancer Res.
Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. 17493236 Histopathology
Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. 17493236 Histopathology
Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior. 23887168 J Thorac Oncol
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. 29596783 Cell Syst
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. 29617668 Cell Rep
Pan-cancer analysis of whole genomes. 32025007 Nature
Pathogenic Germline Variants in 10,389 Adult Cancers. 29625052 Cell
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. 28945830 Ann. Oncol.
Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells. 22761781 PLoS ONE
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. 29625049 Cell
Plasma Anti-Glycan Antibody Profiles Associated with Nickel level in Urine. 24737927 J Proteomics Bioinform
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. 26903362 J Thorac Oncol
Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population. 23568008 Cancer Biomark
Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma. 27447750 Oncotarget
Prediction of lung cancer using volatile biomarkers in breath. 17522431 Cancer Biomark
Pro-tumorigenic effects of miR-31 loss in mesothelioma. 20463022 J. Biol. Chem.
Pro-tumorigenic effects of miR-31 loss in mesothelioma. 20463022 J. Biol. Chem.
Processing and analysis of serum antibody binding signals from Printed Glycan Arrays for diagnostic and prognostic applications. 22112531 Int J Bioinform Res Appl
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. 20616036 Proc. Natl. Acad. Sci. U.S.A.
Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival. 27799870 Clin Proteomics
Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. 24240684 Oncogene
Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. 20085934 J. Clin. Oncol.
Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure. 23045294 Eur J Cardiothorac Surg
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. 22412141 J. Clin. Oncol.
Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. 27002763 Cancer Biomark
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. 18154821 Ann. Thorac. Surg.
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. 18154821 Ann. Thorac. Surg.
Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. 29617667 Cell Rep
Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer. 29129073 J. Proteome Res.
SV40 detection in human tumor specimens. 16267039 Cancer Res.
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. 19960346 Cancer Chemother. Pharmacol.
Telomerase activity in pleural malignant mesotheliomas. 21277646 Lung Cancer
The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. 18949431 Oncol. Rep.
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. 29617669 Cell Rep
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. 29925010 Cell Rep
The Immune Landscape of Cancer. 29628290 Immunity
The Microbiome in Lung Cancer Tissue and Recurrence-Free Survival. 30733306 Cancer Epidemiol. Biomarkers Prev.
The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival. 20010871 Oncogene
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. 29362358 Oncogenesis
Tissue and exosomal miRNA editing in Non-Small Cell Lung Cancer. 29976955 Sci Rep
TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. 16798876 Proc. Natl. Acad. Sci. U.S.A.
Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma. 23851502 Oncogene
Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. 19285954 Biochem. Biophys. Res. Commun.
Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. 21170350 PLoS ONE
Validation of a blood protein signature for non-small cell lung cancer. 25114662 Clin Proteomics
Validation of a multiprotein plasma classifier to identify benign lung nodules. 25590604 J Thorac Oncol
Variant Ciz1 is a circulating biomarker for early-stage lung cancer. 23074256 Proc. Natl. Acad. Sci. U.S.A.
When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All? 30863365 Front Endocrinol (Lausanne)
Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer. 29313979 Int. J. Cancer
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. 25488749 Cancer Res.
Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo. 22912669 PLoS ONE

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.

Version 5.0.2